Phase II
Pfizer has launched a Phase II/III study to assess its oral antiviral Paxlovid in non-hospitalized symptomatic pediatric patients who are at risk for progression to serious disease.
Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.
BioNTech announced an expansion on its collaboration with Regeneron to continue advancing mRNA technology and develop novel treatments for a variety of cancers.
From artificial intelligence breakthroughs to at-home genetic testing, here are some ways COVID-19 has changed the biopharma industry and what we may see in the near future.
Agenus and Targovax partner on a KRAS cancer vaccine, Elixirgen and Taisho target aging and Tonix and Mass General team up again to fight kidney transplant rejection.
The Phase I study could potentially result in RP-A501 becoming the first gene therapy for monogenic heart failure.
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
As COVID-19 cases fall in the wake of the latest surge from the Omicron variant, the question on the minds of many is, what comes next for these Pfizer and Moderna?
The FDA turned down Ocugen’s Emergency Use Authorization request for Covaxin in children 2 to 18, which the company is co-developing with India’s Bharat Biotech.
Six months into the job, Chief Executive Officer Deepa Prasad left vTv Therapeutics. Not long ago, the former CEO dramatically slashed its workforce to ensure funding for its lead diabetes asset.
PRESS RELEASES